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Introduction
The genetically engineered mouse has become an established
tool used to both better understand cancer and develop strate-
gies to treat it, as exemplified by the extensive investigations
ongoing in the National Cancer Institute-sponsored Mouse
Models of Human Cancer Consortium (http://emice.nci.nih.gov).
A now standard technique to validate the role of specific genes
during tumorigenesis is to engineer mice under- or overexpress-
ing the genes of interest. Intercrossing combinations of engi-
neered alterations is a powerful technique to elucidate genetic
interactions contributing to tumorigenesis in vivo.
In a majority of cases, genetically engineered mice display
abnormalities in development or homeostasis, defects that in
some cases appear to preclude the use of these lines in studies
of adult diseases. Nevertheless, such mice are still valuable
tools for cancer researchers, as they serve as predictors of the
effects on the whole organism induced by pharmacological
manipulation of particular gene products. Indeed, intended ther-
apeutic responses of most targeted inhibitors mirror develop-
mental abnormalities in mice with genetic ablation or reduction
of the corresponding target (Zambrowicz and Sands, 2003). As
the postgenomic era creates a burgeoning wave of molecular
targets and combinatorial treatment strategies, approaches to
predict possible toxicities should become integral components
of the drug development process. Mouse models represent one
such tool in that they provide the specificity of a genetic manip-
ulation with a phenotypic readout that involves the whole organ-
ism. Additionally, genetic models overcome some aspects of
pharmacologic toxicity studies in mice, namely metabolic differ-
ences and absence of bioactivity of some agents in mice,
including most antibody-based therapies. Likewise, robust phe-
notypes of genetically engineered mice may be more predictive
of chronic and severe toxicity than relatively short-term treat-
ment of mice with pharmacologic inhibitors, modeling the
extreme reactions that may be observed in the clinic.
The ERBB story
Overexpression of and/or aberrant signaling by ERBB recep-
tors, particularly EGFR and ERBB2, occurs frequently in human
cancer. Consequently, ERBB-targeted therapies consisting of
ligand-blocking antibodies or ATP-competitive small molecule
tyrosine kinase inhibitors have been developed and are in
advanced phases of clinical investigation (Arteaga and
Baselga, 2003). Trials with ERBB-targeted drugs have revealed
uncanny similarities between treatment side effects in patients
and phenotypes in mice with reduced ERBB receptor function
(Table 1). The most common side effect seen with EGFR inhibi-
tion therapy is an acneiform follicular rash of variable severity
(Figure 1). This rash recapitulates the skin and follicle defects
seen in engineered mouse models with low or absent EGFR
activity. Egfr-deficient mice have abnormally dry, flaky, thin skin
and extensive hair follicle defects resulting in thin, brittle hair
(Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et
al., 1995). Likewise, mice homozygous for the hypomorphic
Egfrwa2 allele display wavy coats resulting from hair follicle
defects, often with skin flaking and alopecia (Luetteke et al.,
1994). Egfr null skin shows a mixed inflammatory infiltration at
the follicle with rupture of the follicular epithelium, hallmarks of
skin reactions in patients treated with EGFR antagonists
(Baselga et al., 2002; Busam et al., 2001; Hansen et al., 1997).
Gastrointestinal toxicity has also been seen in these clinical
trials, likely due to disruption of gut homeostasis as indicated by
studies in mice deficient for Egfr or its ligands. These mice
demonstrate a variety of gastrointestinal phenotypes, including
necrotizing enterocolitis, duodenal lesions and perforations,
defects in acid secretion, and delays in healing following surgi-
cal or chemical damage (Egger et al., 2000; Helmrath et al.,
1997; Joshi et al., 1997; Miettinen et al., 1995; Troyer et al.,
2001). Similarly, pulmonary fibrosis and interstitial pneumonia
reported in lung cancer trials with EGFR inhibitors recapitulate
developmental phenotypes from Egfr nullizygous mice, with
proliferation of nonepithelial cells resulting in thickening of the
alveolar walls, reduction of air-filled aveoli, and respiratory dis-
tress (Kanemura et al., 2003; Miettinen et al., 1995; Sibilia and
Wagner, 1995; Suzuki et al., 2003; Teramoto et al., 2003).
Perhaps the most well known toxicity caused by ERBB 
inhibition is cardiac dysfunction. Herceptin (trastuzumab,
Genentech), a humanized antibody against ERBB2, was the
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first ERBB-targeted therapy approved for clinical trials.
Cardiomyopathy, congestive heart failure, and decreases in left
ventricular ejection fraction have been observed, particularly in
patients with cardiac risk factors or those who received concur-
rent anthracyclines (Slamon et al., 2001). Notably, Erbb2 null
mice suffer from a lack of cardiomyocyte differentiation (Lee et
al., 1995). Additionally, cardiac-specific conditional Erbb2
knockouts develop dilated cardiomyopathy prior to the second
postnatal month (Crone et al., 2002; Ozcelik et al., 2002); they
also have reduced survival following cardiac overload, as well
as increased sensitivity to anthracycline-induced cardiomyocyte
death.These results are consistent with the observation of clini-
cal toxicity predominantly in patients with cardiac risk factors
and/or anthracycline therapy. Cardiac toxicity has yet to be
reported following treatment with EGFR-specific antagonists.
However, Egfr mutant mice do exhibit aortic valve overgrowth,
resulting in stenosis and ventricular hypertrophy, the severity of
which varies with genetic background (Chen et al., 2000;
Jackson et al., 2003), suggesting that cardiac toxicity may occur
in some patients on anti-EGFR therapy.
Erbb-deficient mice also exhibit neuronal and sensory
deficits, demonstrating that Erbb receptors are required for prop-
er development and maintenance of the brain and peripheral
nervous system (Britsch et al., 1998; Erickson et al., 1997;
Gassmann et al., 1995; Threadgill et al., 1995). Additionally, the
enteric nervous system develops normally when Erbb2 is ren-
dered null via conditional knockout, but is subsequently lost
postnatally, resulting in a Hirschsprung’s disease-like phenotype
(Crone et al., 2003). At present, no major neurological toxicity
has been reported from clinical studies of ERBB antagonists,
though low-grade peripheral neuropathy has been observed
(Fountzilas et al., 2001; Mrsic et al., 2001). Similarly, no sensory
damage has been reported in patients given EGFR inhibitors
despite the fact that Egfr and Tgfa mutant mice exhibit develop-
mental eye defects, glaucoma, and hearing defects (Mann et al.,
1993; R.B.R. and D.W.T., unpublished data;Thaung et al., 2002).
Given the involvement of ERBB receptors in nervous system
development and maintenance, neurological side effects would
be predicted in some patients treated with ERBB antagonists,
particularly those on extended treatment. This suggests that
neurological and sensory parameters be followed over the
course of treatment to uncover subtle chronic toxicity.
Mice with reduced EGFR activity exhibit follicular defects
that vary with strain background (R.B.R. and D.W.T., unpub-
lished data); likewise, patients taking EGFR inhibitors demon-
strate folliculitis of varying severity. In this way, phenotypic
variation across inbred strains with the same genetic alteration
begins to represent the range of toxic responses seen in a pop-
ulation of patients with heterogeneous genetic backgrounds.
Similarly, most Egfr-related phenotypes, including defects in
viability, heart, eye, and sensory response, also exhibit variable
penetrance and severity depending on genetic background
(R.B.R. and D.W.T., unpublished data; Sibilia and Wagner, 1995;
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Figure 1. Developmental skin defects in Egfr-deficient mice (A and C) and
skin toxicity in patients treated with EGFR inhibitors (B and D)
Gross images of severe skin and hair pathology in a Egfr mutant mouse (A)
and folliculitis in a patient susceptible to EGFR inhibition therapy induced
skin toxicity (B). Comparative histology of hair follicle in Egfr nullizygous skin
(C) and follicle from patient with EGFR therapy-induced folliculitis (D).
Rupture of follicular epithelium and strong mixed inflammatory response
are evident in both C and D. (B) reprinted with permission from the
American Society of Clinical Oncology (Baselga et al., 2002); (C) provided
by Laura Hansen (Creighton University); and (D) reprinted with permission
from Blackwell Publishing (Busam et al., 2001).
Table 1: Erbb-deficient mouse phenotypes and ERBB-inhibitor toxicity in
humans
Erbb-related defects (mouse) ERBB inhibition-related toxicity (human)
Inflammation (Egfr) hypersensitivity (EGFR)
Skin/hair follicle (Egfr) acneiform folliculitis (EGFR)
Heart (Egfr, Erbb2,3,4) cardiac dysfunction and toxicity (ERBB2)
Gut repair/homeostasis (Egfr) diarrhea, stomatitis, vomiting (EGFR)
Neuronal (Egfr, Erbb2,3,4) neuropathy and tremor (EGFR)
Liver (Egfr) hepatotoxicity (EGFR)
Kidney (Egfr) renal effects (EGFR)
Vasoconstriction (Egfr) hypotension (EGFR)
Lung (Egfr) pulmonary fibrosis (EGFR)
Circadian-related activity (Egfr) ?
Eye (Egfr) ?
Skeletal (Egfr) ?
Hearing (Egfr) ?
Sensory gating (Erbb4) ?
Hyperactivity (Erbb4) ?
Skeletal muscle (Erbb2) ?
Lactation (Egfr, Erbb4) ?
Seizure (Egfr) ?
?, unknown.
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Threadgill et al., 1995). Strain-based variance of a phenotype
serves as a foundation to map modifier genes of the phenotype.
In the framework of toxicity studies, such modifiers would
enhance resistance or susceptibility to adverse events in
patients, and thus may serve as biomarkers to predetermine
toxicity and response to therapy. Indeed, the severity of folliculi-
tis induced by EGFR antagonists appears to correlate with
patient survival, suggesting that the rash can be used as a bio-
marker for therapeutic activity (Clark et al., 2003; Saltz et al.,
2003). However, many potentially predictable side effects,
including lethal ones, occur with rarity that prevents mapping in
human populations, and patient numbers in phase I and II clini-
cal trials are usually too low to provide genetic data for modifier
mapping. Fortunately, modifier studies in engineered mice
should elucidate the underlying molecular biology of these indi-
vidual patient responses, allowing for the creation of biomarker
assays to individually predict disease response and the likeli-
hood of side effects, including cardiac, pulmonary, sensory, and
neuronal damage.
Developmental complications
The striking similarities between human responses to ERBB
inhibitors and engineered mouse models is reflected in other
top molecule-based therapies (Table 2). Inhibitors of cyclooxy-
genase-2 (COX2), in addition to modulation of inflammatory
response, can result in renal and cardiovascular toxicity
(Ahmad et al., 2002). These toxicities recapitulate lethal heart
and kidney defects present in Ptgs2 (Cox2) null mice (Dinchuk
et al., 1995; Morham et al., 1995). However, renal disease in the
Ptgs2 knockout mice is the result of developmental dysmorphol-
ogy, and thus does not truly replicate renal dysfunction following
treatment with COX2 inhibitors. Similarly, the variable fibrotic
cardiac phenotype seen in Ptgs2 mouse models differs from
thrombotic events seen in patients treated with COX2 inhibitors
(Bannwarth et al., 2003). Although the pathologies resulting
from genetic and pharmacological insult differ mechanistically,
the engineered mouse models accurately predict the tissues
sensitive to perturbation. Similarly, while mice heterozygous for
a null mutation of Vegf die in utero with abnormal vasculature
and hearts (Ferrara et al., 1996), they remain predictive of toxi-
city in adults observed in clinical trials with the VEGF-blocking
antibody Avastin (bevacizumab). Some patients on Avastin
exsanguinated and died from pulmonary hemorrhage (Johnson
et al., 2004), and others developed gut perforations, hyperten-
sion, proteinuria, and thrombosis (Hurwitz et al., 2003; Yang et
al., 2003). The side effects in Avastin-treated patients can be
attributed to vascular abnormalities and leakage, the root cause
of Vegf-related phenotypes in the mouse. Although mice with
hypoxic expression of Vegf exhibit a striking phenotype of adult-
onset neuronal degeneration, reminiscent of amyotrophic later-
al sclerosis (Oosthuyse et al., 2001), no neurological toxicities
have been reported in VEGF inhibitor trials, though chronic
treatment would likely be necessary to produce such toxicity.
It is clear that some genetically engineered modifications
are highly detrimental during development but have little to no
effect on cellular maintenance in adult animals. In these cases,
simple gene knockouts may not serve as predictors of therapy-
related toxicity in adults with terminally developed organs. The
minimal toxicity following treatment with Gleevec (imatinib
mesylate, Novartis), which inhibits activity of ABL, PDGFR, and
KIT kinases, serves as an example. Mice nullizygous for any of
these targets are essentially nonviable, with hemorrhagic and
anemic phenotypes, and, depending on the mutation, a variety
of developmental defects (Schwartzberg et al., 1991; Soriano,
1994, 1997;Tybulewicz et al., 1991). Aside from some reports of
anemia, thrombosis, and hair pigmentation in Gleevec-treated
patients, all predicted from abnormalities in the genetically engi-
neered mouse models, there have been no other toxicities
reported. Interestingly, the small molecule inhibitor of c-Kit,
VEGFR, and PDGFR, SU11248 (Pfizer) causes hair depigmen-
tation in patients (Moss et al., 2003; Robert et al., 2003), an
obvious prediction from the white spot coat pattern of mice with
Kit mutations (Little and Cloudman, 1937).
Conditional null alleles overcome both confounding devel-
opmental defects and any molecular compensation resulting
from development in the absence of a gene product. For exam-
ple, embryonic fibroblasts from mice homozygous for a knock-
out of the retinoblastoma (Rb1) gene senescence normally,
apparently having adapted for lack of RB by upregulating the
Rb1-like gene p107 (Rbl1) during development. Similar cells
homozygous for a conditional null Rb1 allele do not have altered
p107 levels, and thus proliferate unchecked following acute
removal of the Rb1 gene (Sage et al., 2003). Use of such tem-
poral null alleles will also allow toxicity-predictive studies of tar-
get genes whose traditional knockout would result in pre- or
perinatal death, and tissue-specific knockout would allow the
modeling of delivery of molecular therapeutics. A study utilizing
a temporal tissue-specific knockout strategy removed the TGFβ
type II receptor (Tgfbr2) gene from hematopoietic cells of adult
mice (Leveen et al., 2002). Within two months following Tgfbr2
removal, mice exhibit massive autoimmune inflammation and
multiorgan necrosis, with a paralysis-like phenotype and ulti-
mately death.These results imply that autoimmune phenomena
and organ inflammation should be prospectively examined in
patients receiving inhibitors of TGFβ signaling currently in
development (Dumont and Arteaga, 2003).
R E V I E W
Table 2: Toxicity predictions from mouse models for targets of clinical
interest
Target Toxicity predicted from genetically engineered mouse models
COX2 kidney, heart
VEGF vasculature, heart, neuronal 
PDGF vasculature, skin, bone
ABL spleen, bone, immune system, eye, heart, nervous system,
sensory, behavior
KIT pigmentation, anemia, sterility
TGFBR inflammation, spleen, bone, liver, lung, vasculature, heart, 
thymus, eye, hearing, nervous system, paralysis
SRC bone
TRP53 (p53) accelerated ageing/degeneration of all tissues
AKT diabetes, skin/hair, lung, muscle, bone, reduced lifespan
IGFR diabetes, bone, lung, muscle, nervous system
PI3K cancer, diabetes, immune system, liver, muscle, heart
BCL2 spleen, thymus, kidney
ESR infertility, bone, diabetes, eye, nervous system, anxiety,
aggression, myeloproliferation, prostate and bladder 
hyperplasia
RAR infertility
Boldface, adverse events observed in patients. Only a few of the targets
listed are currently in clinical trials.
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Degenerative models
Some genetically engineered mice exhibit degenerative pheno-
types without any developmental defects. For example, Src null
mice are viable but develop osteopetrosis due to defects in osteo-
clast function (Lowe et al., 1993; Soriano et al., 1991). The Src
knockout mouse predicts an otherwise nonintuitive phenotypic
outcome in patients, and thus the inclusion of bone density mea-
surements is under consideration for trials with SRC inhibitors.
Another key example is the Akt1 knockout mouse, which exhibits
increased sensitivity and reduced lifespan in response to geno-
toxic stress (Chen et al., 2001). Thus, combinations of AKT
inhibitors with chemotherapy or radiotherapy may synergize and
induce profound toxicities in normal tissues as well. Akt2 null mice
exhibit glucose intolerance (Garofalo et al., 2003), implying that
AKT inhibitors may also induce or exacerbate a diabetic condi-
tion. Genetic inactivation of other genes involved in glucose
homeostasis also leads to a diabetic phenotype, including such
potential cancer therapy targets as the insulin-like growth factor
receptors and phosphatidylinositol 3-kinase (Fruman et al., 2000;
Terauchi et al., 1999; Zhang et al., 2002). Therefore, serum glu-
cose should be monitored in diabetic and nondiabetic patients
enrolled in trials with IGF and PI3K antagonists.
Modes of activation and reconstitution of the tumor suppres-
sor p53 (Trp53) are currently in development to place uncon-
trolled cell proliferation in check (Chene, 2003; Moon et al.,
2003). Important lessons can be learned from degenerative phe-
notypes produced in mouse models of p53 hyperactivity to fore-
tell potential complications of such strategies as cancer therapy.
Genetically engineered mouse models of p53 hyperactivation
produce mice that are less susceptible to both spontaneous and
induced cancers (Garcia-Cao et al., 2002; Tyner et al., 2002).
While one mouse model of increased p53 activity has pheno-
types associated with premature aging, including reduced lifes-
pan and progressive degenerative defects (Tyner et al., 2002), a
second model showed a beneficial tumor resistance phenotype
without the negative aging-related defects (Garcia-Cao et al.,
2002).The degenerative phenotypes were observed when using
a modified Trp53 gene, a C-terminal truncated protein apparent-
ly capable of maintaining the wild-type p53 protein in an activat-
ed state. In contrast, the mice that appeared to be free of major
degenerative defects were created by adding an extra copy of
wild-type Trp53 gene in its genomic context, thereby increasing
normal gene dosage while maintaining endogenous expression
and feedback regulation of Trp53 at the transcriptional and pro-
tein level. Since the former study more closely models the effects
of pharmacological activation of p53, that is, addition of an
exogenous activator of p53 that uncouples it from normal cellular
regulation, its results throw strong caution at potent activation of
p53, especially for chronic courses or for those already afflicted
by degenerative or aging-related disease. These studies can
also be used to suggest potentially safe parameters for treat-
ment-induced activation of p53.
Targeted toxicity models
Eventually, the risk of adverse side effects from targeted therapy
may be greatly lessened by using a low dose combinatorial
approach, targeting a set of molecules customized for individual
disease and patient. Likewise, targeted therapy may allow pre-
ventive or senescent strategies that would necessitate chronic
treatment in the span of years to maintain a carcinoma-free
state. The use of genetically engineered mice may help predict
side effects unique to extended treatment and thus not uncov-
ered during relatively brief clinical trials or treatment regimens.
The cost for the creation and phenotypic analysis of a targeted
toxicity mouse model pales in comparison to the expense of a
single clinical trial, especially if the trial is confounded by unex-
pected morbidity. Even if a transgenic mouse is engineered to
ask a specific question, full phenotypic analysis is essential to
uncover unexpected phenotypes that may predict toxicity. As a
prime example of a significant, “hidden” phenotype, mice carry-
ing the Egfrwa2 mutation were maintained for over sixty years
before heart valve abnormalities and ventricular hypertrophy
were discovered—phenotypes that may prove relevant to clini-
cal treatment with EGFR inhibitors.
As combinatorial targeted therapy becomes a practical real-
ity, the combination of multiple targeted genes in a single mouse
line may produce phenotypes that anticipate unique toxicity
resulting from additive or synergistic therapeutic effects. For
example, EGFR and COX2 inhibitors are in the forefront of tar-
geted therapies for colorectal cancer prevention and treatment,
and mice with defects in Egfr or Ptgs2 activity individually
demonstrate cardiac and renal abnormalities. Crossing lines
carrying conditional null alleles would produce a mouse model
of simultaneous ablation of EGFR and COX2 activity during
adulthood, potentially uncovering side effects specific to dual
inhibition. Similarly, potential toxic synergy can be uncovered by
treating mice carrying a mutation in one target with a pharma-
cologic inhibitor against the other target. This latter method is
particularly practical if mice are unavailable or nonviable with a
mutation in a gene of interest.
Perspective
In the end, genetic ablation of a target protein may demonstrate
potential toxicities not revealed by incomplete or short-term
pharmacological inhibition, modeling the worst-case scenario
for therapeutic side effects.The defects seen in genetically engi-
neered mice may thus represent expectations in a small subset
of patients whose genetic background makes them particularly
susceptible to severe adverse effects when targeting a particu-
lar molecular pathway. Similarly, the use of mouse models has
demonstrated the importance of genetic background to pheno-
types resulting from the perturbation of a pathway. Analysis of
mouse models of therapy toxicity on multiple inbred back-
grounds will add a level of complexity and cost, but with the
potential benefit to allow mapping of loci involved in interindivid-
ual variation in toxicity susceptibility. Mapping experiments,
especially if properly combined with expression and proteome
studies, may allow the identification of biomarkers or gene poly-
morphisms modulating toxicity susceptibility, thus providing an
avenue for simple tests to anticipate and detect side effects,
such as the TMPT gene test for 6-mercaptourine (6MP) toxicity
susceptibility (Marshall, 2003).
Analysis of genetically engineered mouse models with fore-
thought to toxicity may greatly reduce the morbidity associated
with unexpected toxicities caused by molecule-targeted thera-
pies when introduced into the clinic. More detailed analysis of
these mouse models will provide the foundation for dissecting
the complexity of individual patients, thus providing strategies
for “rational utilization” that will inevitably follow intense efforts
put into the “rational design” of targeted therapies. Only follow-
ing an understanding of the genetic basis of resistance and sus-
ceptibility to side effects will truly customized therapy be a
reality—maximizing disease response while minimizing toxicity
to the patient.
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